top of page
  • Recruiting

NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies

Updated: May 25, 2022

NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies


GEN3014

GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies


This trial is an open-label, safety trial of GEN3014 (HexaBody®-CD38). The trial consists of two parts: a dose escalation part phase 1, first-in-human (FIH), and an expansion part phase 2a.


Sponsor


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT04824794


Official Title: An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies


First Posted : April 1, 2021


Click here to see details on ClinicalTrials.gov

 

Biological: GEN3014 (HexaBody®-CD38)

Anti-CD38 Monoclonal Antibody GEN3014 (Code C179514)

Anti-CD38 Monoclonal Antibody GEN3014

GEN 3014

GEN-3014

GEN3014

HexaBody-CD38

 

Locations

United States, New Jersey

United States, North Carolina

United States, Wisconsin

Europe

Spain

Denmark

Sweden





Comments


Posts Archive
bottom of page